1. Home
  2. EVEX vs ANL Comparison

EVEX vs ANL Comparison

Compare EVEX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eve Holding Inc.

EVEX

Eve Holding Inc.

HOLD

Current Price

$2.84

Market Cap

895.1M

Sector

Industrials

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.00

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVEX
ANL
Founded
2020
2004
Country
United States
United States
Employees
198
N/A
Industry
Aerospace
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
895.1M
731.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
EVEX
ANL
Price
$2.84
$10.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$6.88
$20.00
AVG Volume (30 Days)
956.4K
98.0K
Earning Date
05-05-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
$11,676.47
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.34
$0.88
52 Week High
$7.70
$17.25

Technical Indicators

Market Signals
Indicator
EVEX
ANL
Relative Strength Index (RSI) 46.00 41.90
Support Level $2.81 $9.46
Resistance Level $3.18 $12.59
Average True Range (ATR) 0.19 1.12
MACD -0.03 -0.03
Stochastic Oscillator 31.68 17.66

Price Performance

Historical Comparison
EVEX
ANL

About EVEX Eve Holding Inc.

Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: